InVivo Therapeutics Shares Resume Trade
$NVIV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
InVivo Therapeutics Shares Resume Trade
Save time and jump to the most important pieces.
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)
Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company's INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not meet its primary endpoint, which was assessed by the proportion of tre
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company's common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or
4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
4/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
3 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside
Gainers BioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market cap stands at $8.9 million. Coeptis Therapeutics (NASDAQ:COEP) shares rose 6.64% to $0.48. The market value of their outstanding shares is at $16.3 million. Alzamend Neuro (NASDAQ:ALZN) stock rose 6.56% to $0.97. The market value of their outstanding shares is at $6.4 million. China Pharma Holding (AMEX:CPHI) stock increased by 5.7% to $0.1. The company's market cap stands at $5.3 million. AIM ImmunoTech (AMEX:AIM) shares rose 5.54% to $0.45. The market value of their outstanding shares is at $21.9 million. Better Therapeutics (NASDAQ:BTTX) stock moved u
Shares of Big Lots, Inc. (NYSE:BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ:MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ:BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated vide
Gainers Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. Regencell Bioscience (NASDAQ:RGC) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million. Genenta Science (NASDAQ:GNTA) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million. T2 Biosystems (NASDAQ:TTOO) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million. Sangamo Therapeutics (NASDAQ:SGMO) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million. Organovo Holdings (NASDAQ:ONVO) shares m
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)
SC 13G/A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Subject)